Showing results (81-90 of 259) with videos related to
Sort By:
Pageof 26
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2017
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of OsimertinibSuzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, et al.Therapeutic Advances in Medical Oncology|May 25, 2026
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with <i>EGFR</i>-mutated locally advanced or metastatic non-small cell lung cancerShun Lu, Mariano Provencio Pulla, Eldsamira Mascarenhas, et al.Cancer Research and Treatment|July 27, 2019
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II StudiesMyung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, et al.Plos One|January 1, 2016
The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic DiseasesYun Chiang, James Chih-Hsin Yang, Feng-Ming Hsu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 12, 2018
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR MutationJames Chih-Hsin Yang, Shirish M Gadgeel, Lecia VanDam Sequist, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival BenefitEmily Pei-Ying Lin, Chih-Yuan Hsu, Jeng-Fong Chiou, et al.Journal of Cancer|July 30, 2016
Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily PracticeYi-Hsin Liang, Yu-Yun Shao, Bin-Chi Liao, et al.Clinical Lung Cancer|February 4, 2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Filippo de Marinis, Federico Cappuzzo, et al.Oncotarget|April 15, 2015
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancerYi-Nan Liu, Tzu-Hua Chang, Meng-Feng Tsai, et al.Pageof 26